United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Has $2.66 Million Stock Holdings in Cencora, Inc. $COR

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its stake in Cencora, Inc. (NYSE:COR) by 174.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,500 shares of the company’s stock after buying an additional 5,400 shares during the quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Cencora were worth $2,657,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. IAG Wealth Partners LLC purchased a new position in shares of Cencora during the 3rd quarter valued at $30,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares in the last quarter. Cloud Capital Management LLC purchased a new stake in shares of Cencora during the third quarter worth $31,000. Caitlin John LLC acquired a new stake in Cencora during the third quarter valued at $31,000. Finally, Westside Investment Management Inc. boosted its position in Cencora by 200.0% during the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after purchasing an additional 70 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 15,220 shares of company stock worth $5,282,867. 0.38% of the stock is owned by insiders.

Analysts Set New Price Targets

COR has been the topic of several research reports. Bank of America dropped their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Wells Fargo & Company lifted their price target on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Barclays boosted their price target on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. TD Cowen increased their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, Evercore cut their price objective on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $399.00.

Cencora Stock Down 0.4%

Shares of COR stock opened at $357.98 on Friday. The stock’s 50 day simple moving average is $354.16 and its 200 day simple moving average is $336.45. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora, Inc. has a twelve month low of $251.94 and a twelve month high of $377.54. The company has a market capitalization of $69.64 billion, a price-to-earnings ratio of 43.03, a PEG ratio of 1.67 and a beta of 0.68.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter in the prior year, the business earned $3.73 earnings per share. The company’s revenue was up 5.5% on a year-over-year basis. As a group, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.